Soft Tissue Sarcoma
Histopathology Reporting Guide
Resection Specimens

Family/Last name

Given name(s)

Date of birth DD – MM – YYYY

Patient identifiers

Date of request DD – MM – YYYY

Accession/Laboratory number

Elements in **black text** are CORE. Elements in **grey text** are NON-CORE.

SCOPE OF THIS DATASET

☐ indicates multi-select values ◯ indicates single select values

CLINICAL INFORMATION (select all that apply)

- ◯ Information not provided
- ☐ Familial syndrome, *specify*
- ☐ Multifocal disease, *specify*
- ☐ Other, *specify*

NEOADJUVANT THERAPY

- ◯ Information not provided
- ◯ Not administered
- ◯ Administered (select all that apply)
  - ☐ Neoadjuvant chemotherapy
  - ☐ Neoadjuvant radiotherapy
  - ☐ Other, *describe*

OPERATIVE PROCEDURE (select all that apply)

- ◯ Not specified
- ☐ Resection, *specify if known*
- ☐ Amputation, *specify type*
- ☐ Other, *specify*

TUMOUR SITE (select all that apply)

- ◯ Not specified
- ☐ Cutaneous, *specify deeper extension if known*
- ☐ Head and neck, *specify site if known*
- ☐ Trunk, *specify site and depth if known*
- ☐ Extremities, *specify site and depth if known*

  Specify laterality
  - ◯ Left
  - ◯ Right
  - ◯ Not specified
- ☐ Abdominal/pelvic visceral organ(s), *specify site if known*
- ☐ Thoracic visceral organ(s), *specify site if known*
- ☐ Thoracic soft tissue (including mediastinum), *specify site if known*
- ☐ Retroperitoneum (including paratesticular), *specify site if known*
- ☐ Pelvis, *specify site if known*
- ☐ Other somatic or visceral site, *specify site if known*

Version 1.1 Published April 2021 ISBN: 978-1-922324-19-1

TUMOUR DEPTH – TISSUE PLANE (select all that apply)

- ◯ Cannot be assessed
- ◯ Not known
- ☐ Cutaneous
- ☐ Subcutaneous
- ☐ Subfascial/muscle
- ☐ Bone
- ☐ Abdominal/retroperitoneal
- ☐ Other, *specify*

TUMOUR DIMENSIONS

Maximum tumour dimension ____ mm

Additional dimensions ____ mm x ____ mm

OR

- ◯ No identifiable tumour (e.g., after preoperative therapy)
- ◯ Cannot be assessed, *specify*

HISTOLOGICAL TUMOUR TYPE

(Value list based on the World Health Organization Classification of Soft Tissue and Bone Tumours (2020))

- ◯ No residual tumour
- ◯ Atypical lipomatous tumour
- ◯ Liposarcoma, well-differentiated, *specify type*
- ◯ Dedifferentiated liposarcoma
- ◯ Myxoid liposarcoma
- ◯ Pleomorphic liposarcoma
- ◯ Dermatofibrosarcoma protuberans NOS
  - ◯ Dermatofibrosarcoma protuberans, fibrosarcomatous
- ◯ Solitary fibrous tumour NOS
- ◯ Inflammatory myofibroblastic tumour
  - ◯ Epithelioid inflammatory myofibroblastic sarcoma
- ◯ Myxoinflammatory fibroblastic sarcoma
- ◯ Infantile fibrosarcoma
- ◯ Fibrosarcoma NOS
- ◯ Myxofibrosarcoma
  - ◯ Epithelioid myxofibrosarcoma
- ◯ Low grade fibromyxoid sarcoma
- ◯ Sclerosing epithelioid fibrosarcoma
- ◯ Plexiform fibrohistiocytic tumour
- ◯ Giant cell tumour of soft parts
- ◯ Haemangioendothelioma, *specify type*[a]
- ◯ Kaposi sarcoma, *specify epidemiologic type*
- ◯ Epithelioid haemangioendothelioma NOS
  - ◯ Epithelioid haemangioendothelioma with *WWTR1-CAMTA1* fusion
  - ◯ Epithelioid haemangioendothelioma with *YAP1-TFE3* fusion
- ◯ Angiosarcoma
- ◯ Glomus tumour, malignant
- ◯ Leiomyosarcoma NOS
- ◯ Embryonal rhabdomyosarcoma NOS
  - ◯ Embryonal rhabdomyosarcoma, pleomorphic
- ◯ Alveolar rhabdomyosarcoma
- ◯ Pleomorphic rhabdomyosarcoma NOS
- ◯ Spindle cell rhabdomyosarcoma
- ◯ Osteosarcoma, extraskeletal
- ◯ Malignant peripheral nerve sheath tumour NOS
  - ◯ Malignant peripheral nerve sheath tumour, epithelioid
- ◯ Malignant melanotic nerve sheath tumour
- ◯ Atypical fibroxanthoma
- ◯ Angiomatoid fibrous histiocytoma
- ◯ Ossifying fibromyxoid tumour NOS
- ◯ Synovial sarcoma, *specify type*
- ◯ Epithelioid sarcoma
  - ◯ Proximal or large cell epithelioid sarcoma
  - ◯ Classic epithelioid sarcoma
- ◯ Alveolar soft part sarcoma
- ◯ Clear cell sarcoma of soft tissue
- ◯ Extraskeletal myxoid chondrosarcoma
- ◯ Desmoplastic small round cell tumour
- ◯ Rhabdoid tumour of soft tissue
- ◯ Perivascular epithelioid tumour, malignant
- ◯ Myoepithelial carcinoma
- ◯ Mixed tumour, malignant, NOS
- ◯ Undifferentiated sarcoma
- ◯ Spindle cell sarcoma, undifferentiated
- ◯ Pleomorphic sarcoma, undifferentiated
- ◯ Round cell sarcoma, undifferentiated
- ◯ Ewing sarcoma
- ◯ Other round cell sarcoma, *specify*
- ◯ Sarcoma of uncertain type, *specify whether unclassifiable or requires additional testing*
- ◯ Soft tissue tumour of uncertain biologic potential, *specify type where known*
- ◯ Other, *specify*

Diagnosis based on (select all that apply)

- ◯ Not applicable
- ☐ Morphology
- ☐ Immunohistochemistry
- ☐ Molecular testing

[a] *e.g., Kaposiform, Retiform, Pseudomyogenic, Composite or Papillary Intralymphatic angioendothelioma.*

Version 1.1 Published April 2021 ISBN: 978-1-922324-19-1

HISTOLOGICAL TUMOUR GRADE[b]

- ◯ Grade 1
- ◯ Grade 2
- ◯ Grade 3
- ◯ Cannot be assessed, *specify*

[b] *Histological tumour grade is required only for specific histotypes – refer to Note, Table 3.*

MITOTIC COUNT[c]

/2 mm^2

- ◯ Cannot be assessed

[c] *10 HPFs approximates to 2 mm^2 on most modern microscopes, but the number of fields to be counted to encompass 2 mm^2 should ideally be calculated on individual microscopes – refer to HISTOLOGICAL TUMOUR GRADE, Table 3.*

NECROSIS[d]

- ◯ Not identified
- ◯ Present

%

[d] *Necrosis is required for those sarcomas that are gradable – refer to HISTOLOGICAL TUMOUR GRADE, Table 3.*

LYMPHOVASCULAR INVASION

- ◯ Not identified
- ◯ Present
- ◯ Indeterminate

RESPONSE TO NEOADJUVANT THERAPY

- ◯ No prior treatment
- ◯ No response
- ◯ Response
  - % viable tumour %
  - % necrosis %
  - % therapy-induced tissue changes (e.g., fibrosis or hyalinization) %
  - % of cell differentiation (e.g., myxoid liposarcoma) %
- ◯ Cannot be assessed, *explain reasons*

MARGIN STATUS

- ◯ Cannot be assessed
- ◯ Not involved (R0)
  - Distance of tumour from closest margin mm
  - Specify closest margin, if possible
  - Specify distance to other margin(s), if relevant mm
- ◯ Microscopically involved (R1)
  - Specify margin(s), if possible
- ◯ Macroscopically involved (R2)
  - Specify margin(s), if possible

LYMPH NODE STATUS

- ◯ Cannot be assessed
- ◯ No nodes submitted or found

Number of lymph nodes examined

- ◯ Not involved
- ◯ Involved
  - Number of involved lymph nodes
  - ◯ Number cannot be determined

COEXISTENT PATHOLOGY

- ◯ None identified
- ◯ Present (select all that apply)
  - ☐ Neoplastic pathology, *specify*
  - ☐ Non-neoplastic pathology, *specify*
  - ☐ Other, *specify*

Version 1.1 Published April 2021 ISBN: 978-1-922324-19-1

ANCILLARY STUDIES

- ◯ Not performed
- ◯ Performed (select all that apply)
  - ☐ Immunohistochemistry, *specify test(s) and result(s)*
  - ☐ Molecular findings, *specify test(s) and result(s)*
  - ☐ Other, *specify test(s) and result(s)*

HISTOLOGICALLY CONFIRMED DISTANT METASTASES

- ◯ Not identified
- ◯ Present, *specify site(s)*

PATHOLOGICAL STAGING (UICC TNM 8th edition)[e]

TNM Descriptors (only if applicable) (select all that apply)

- ☐ m - multiple primary tumours
- ☐ r - recurrent
- ☐ y - post-therapy

Primary tumour (pT)

- ◯ Inadequate specimen for assessment
- ◯ TX Primary tumour cannot be assessed
- ◯ T0 No evidence of primary tumour

EXTREMITY AND SUPERFICIAL TRUNK

- ◯ T1 Tumour 5 cm or less in greatest dimension
- ◯ T2 Tumour more than 5 cm but no more than 10 cm in greatest dimension
- ◯ T3 Tumour more than 10 cm but no more than 15 cm in greatest dimension
- ◯ T4 Tumour more than 15 cm in greatest dimension

RETROPERITONEUM

- ◯ T1 Tumour 5 cm or less in greatest dimension
- ◯ T2 Tumour more than 5 cm but no more than 10 cm in greatest dimension
- ◯ T3 Tumour more than 10 cm but no more than 15 cm in greatest dimension
- ◯ T4 Tumour more than 15 cm in greatest dimension

HEAD AND NECK

- ◯ T1 Tumour 2 cm or less in greatest dimension
- ◯ T2 Tumour more than 2 cm but no more than 4 cm in greatest
- ◯ T3 Tumour more than 4 cm in greatest dimension
  - ◯ T4a Tumour invades the orbit, skull base or dura, central compartment viscera, facial skeleton, and or pterygoid muscles
  - ◯ T4b Tumour invades the brain parenchyma, encases the carotid artery, invades prevertebral muscle or involves the central nervous system by perineural spread

THORACIC AND ABDOMINAL VISCERA

- ◯ T1 Tumour confined to a single organ
  - ◯ T2a Tumour invades serosa or visceral peritoneum
  - ◯ T2b Tumour with microscopic extension beyond the serosa
- ◯ T3 Tumour invades another organ or macroscopic extension beyond the serosa
  - ◯ T4a Multifocal tumour involving no more than two sites in one organ
  - ◯ T4b Multifocal tumour involving more than two sites but not more than five sites
  - ◯ T4c Multifocal tumour involving more than five sites

Regional lymph nodes (pN)

- ◯ No nodes submitted or found
- ◯ NX Regional lymph nodes cannot be assessed
- ◯ N0 No regional lymph node metastasis
- ◯ N1 Regional lymph node metastasis

[e] *Reproduced with permission. Source: UICC TNM Classification of Malignant Tumours, 8th Edition, eds by James D. Brierley, Mary K. Gospodarowicz, Christian Wittekind. 2016, Publisher Wiley (incorporating any errata published up until 6th October 2020).*

Version 1.1 Published April 2021 ISBN: 978-1-922324-19-1